Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
(NASDAQ: EVAX) Delayed: 3.39 -0.03 (0.88%)
Previous Close $3.42    52 Week High $ 
Open $3.40    52 Week Low $ 
Day High $3.60    P/E N/A 
Day Low $3.38    EPS $ 
Volume 11,474